Skip to main navigation Skip to search Skip to main content

A Phase 3, multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and tolerability of dimebon (PF-01913539) for up to 26 weeks in patients with mild to moderate Alzheimer's disease

Project: Research

Project Details

StatusFinished
Effective start/end date04/1/09 → 12/31/10

Funding

  • Pfizer Incorporated: $25,829.27